EP1073751A2 - Polypeptide presentant des proprietes immunogenes et des fonctions biologiques modifiees d'une proteine - Google Patents

Polypeptide presentant des proprietes immunogenes et des fonctions biologiques modifiees d'une proteine

Info

Publication number
EP1073751A2
EP1073751A2 EP99932615A EP99932615A EP1073751A2 EP 1073751 A2 EP1073751 A2 EP 1073751A2 EP 99932615 A EP99932615 A EP 99932615A EP 99932615 A EP99932615 A EP 99932615A EP 1073751 A2 EP1073751 A2 EP 1073751A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
protein
dna
polypeptide according
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99932615A
Other languages
German (de)
English (en)
Inventor
Lutz Gissmann
Ingrid Jochmus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deutsches Krebsforschungszentrum DKFZ
Original Assignee
Deutsches Krebsforschungszentrum DKFZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforschungszentrum DKFZ filed Critical Deutsches Krebsforschungszentrum DKFZ
Publication of EP1073751A2 publication Critical patent/EP1073751A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to a polypeptide which has immunogenic properties and modified biological functions of a protein, a DNA encoding such a polypeptide and a method for producing such a polypeptide.
  • the invention further relates to the use of the DNA and the polypeptide for active immunization and antibodies directed against the polypeptide.
  • a protein When an animal or human is actively immunized, a protein is often administered as an immunogen, against which antibodies or cytotoxic T cells are then induced.
  • the applicant's recent experiments indicate that such a protein can remain in the body of the animal or human being for a very long time. This applies in particular if the protein is administered in the form of an expression plasmid encoding it.
  • the animal or man has long been involved in the biological functions of the protein, which e.g. may be toxic or transforming. This leads to considerable stress on the animal or humans, the consequences of which are not foreseeable at all.
  • the present invention is therefore based on the object of providing a means by which active immunization can be carried out without the above disadvantages.
  • the present invention thus relates to a polypeptide with immunogenic properties and modified biological functions of a protein and to a DNA coding for such a polypeptide. These agents allow active immunization without the animal or human being at least fully see functions of the protein is exposed.
  • the present invention is based on the knowledge of the applicant that a polypeptide which has sections of a protein of about 10-40 amino acids in an arrangement which has been changed to the protein has an immunogenicity comparable to that of the protein, but has changes in the biological functions of the protein , which may even be missing entirely.
  • the applicant has further recognized that it is favorable for the immunogenicity of such a polypeptide if it contains parts of about 10-20 amino acids which are present in the protein as transitions between the individual sections.
  • a polypeptide which contains sections of the HPV16-E7 protein in an arrangement changed to the E7 protein and further parts present in the E7 protein as transitions between the individual sections is indicated in FIG. 1.
  • the knowledge of the applicant is used to provide a polypeptide with immunogenic properties and modified biological functions of a protein, the polypeptide having sections of the protein of about 10-40 amino acids in an arrangement that has been changed to the protein.
  • protein includes any protein that has immunogenic properties, e.g. the ability to induce antibodies directed against the protein or cytotoxic T cells, and can have biological functions. Examples of such a protein are toxic or transforming proteins.
  • the former can be bacterial toxins or viral proteins that are expressed in persistent infections.
  • An example of such viral proteins is HIV-Tat.
  • Transforming proteins can be of cellular origin, e.g. a melanoma-specific antigen (MAGE). They can also be infected by viruses, e.g. human pathogenic papilloma viruses (HPV), such as HPV 16 or 18. Proteins of such viruses include in particular the proteins E6 and E7.
  • polypeptide with immunogenic properties and altered biological functions of a protein includes any polypeptide, one or all can have immunogenic properties of a protein, whereby one to all biological functions of the protein can be changed, in particular switched off.
  • a polypeptide has sections of the protein of about 10-40 amino acids, in particular 20-30 amino acids, in an arrangement that has been changed to the protein. It can be advantageous if the sections differ from the corresponding sections in the protein by one or more amino acids. These can be, for example, amino acids which are beneficial for the production of the polypeptide and / or the immunogenicity of the sections.
  • polypeptide also contains parts of about 10-20 amino acids, in particular 18-20 amino acids, which are present in the protein as transitions between the individual sections. Such parts can be present at any point in the polypeptide, in particular at the N- and / or C-terminus, individually or as a whole.
  • a preferred polypeptide of the present invention comprises the amino acid sequence indicated in FIG. 1 or an amino acid sequence different therefrom by one or more amino acids.
  • Such a polypeptide comprises sections of the E7 protein from HPV 16 in an arrangement which has been changed to the protein and parts of the E7 protein which are present therein as transitions between the individual sections.
  • an amino acid sequence different from one or more amino acids indicates that the DNA sequence on which this amino acid sequence is based hybridizes with the DNA of FIG. 1.
  • the DNA sequence can differ from the DNA of FIG. 1 by additions, substitutions, deletions and / or inversions of one or more base pairs.
  • hybridization indicates that this takes place under usual conditions, in particular at 20 ° C. below the melting point of the DNA sequence.
  • Another object of the present invention is a nucleic acid coding for a polypeptide above.
  • This can be an RNA or a DNA.
  • a DNA is preferred which comprises the following: (a) The DNA of Fig. 1 or a DNA different therefrom by one or more base pairs, or
  • a DNA different by one or more base pairs indicates that this DNA hybridizes with the DNA of FIG. 1.
  • the former DNA can differ from the DNA of FIG. 1 by additions, substitutions, deletions and / or inversions of one or more base pairs.
  • hybridization reference is made to the above statements.
  • a DNA according to the invention can be present as such or in a vector, in particular an expression vector.
  • an expression vector for E. coli these are e.g. pGEMEX, pUC derivatives, pGEX-2T, pET3b, Biuscript and pQE-8.
  • yeast e.g. to call pY100 and Ycpadl
  • animal cells e.g. pKCR, pEFBOS, cDM8 and pCEV4 must be specified.
  • the baculovirus expression vector pAcSGHisNT-A is particularly suitable for expression in insect cells.
  • suitable cells for expressing a DNA according to the invention which is present in an expression vector.
  • suitable cells include the E. coli strains HB101, DH1, x1776, JM101, JM 109, BL21 and SG 13009, the latter being preferred, the yeast strain Saccharomyces cerevisiae and the animal cells L, 3T3, FM3A, CHO, COS , Vero and HeLa and the insect cells sf9 or Hi5.
  • DNA according to the invention has to be inserted into an expression vector. He is also aware that this DNA can be inserted in connection with a DNA coding for another polypeptide, so that the DNA according to the invention can be expressed in the form of a fusion polypeptide. Furthermore, the person skilled in the art knows conditions, transformed or transfected cells. to cultivate. He is also aware of processes for isolating and purifying the polypeptide expressed by the DNA according to the invention.
  • Another object of the present invention is an antibody directed against an above polypeptide or fusion polypeptide.
  • Such an antibody can be produced by conventional methods. It can be polyclonal or monoclonal. For its production, it is favorable to immunize animals, in particular rabbits or chickens for a polyclonal and mice for a monoclonal antibody, with an above (fusion) protein or fragments thereof. Further “boosters" of the animals can be carried out with the same (fusion) protein or fragments thereof. The polyclonal antibody can then be obtained from the serum or egg yolk of the animals. For the monoclonal antibody, animal spleen cells are fused with myeloma cells.
  • a DNA according to the invention can be expressed directly in animals or humans.
  • the DNA according to the invention can be present in expression vectors which are derived from plasmid and / or virus vectors.
  • virus vectors include AAV, adenovirus and vaccinia virus vectors.
  • the person skilled in the art knows methods of introducing and expressing a DNA according to the invention in animals or humans.
  • Another object of the present invention is a vaccination agent comprising:
  • auxiliaries such as buffers, solvents and carriers.
  • Such a vaccination agent is suitable for active immunization, for example against HPV. If the vaccination agent contains an antibody (c) according to the invention instead of (a) and / or (b), it is suitable for passive immunization, for example against HPV.
  • Another object of the present invention is a kit comprising:
  • auxiliaries such as buffers, solvents, carriers and controls.
  • One or more representatives of the individual components of the vaccination agent or of the kit can be present.
  • the present invention provides polypeptides which have immunogenic properties and modified, in particular deactivated, biological functions of a protein.
  • the present invention further provides DNAs encoding such polypeptides.
  • animals or humans can be actively immunized; in particular, the DNAs can achieve high efficiency in inducing antibodies directed against the protein and, above all, cytotoxic T cells.
  • the agents are characterized in that the immunized animals or humans are not exposed to the stresses that occur with conventional active immunizations.
  • means are provided by the antibodies according to the invention with which the active immunization and its course can be monitored. At the same time, the antibodies are also agents that can be used for passive immunization.
  • the present invention thus makes a major contribution to the development of modern methods in the prophylaxis and therapy of diseases.
  • FIG. 1 shows the base sequence (b) and (c) and the amino acid sequence (a) and (b) derived therefrom of a polypeptide according to the invention which has HPV16-E7 sections. Sections a, b, c and d of the natural HPV16 protein are indicated. The transitions a / b, b / c and c / d are also given. Underlined sequences represent additional amino acids due to the introduced restriction enzyme cleavage sites.
  • 2 shows the base sequence (b) and the amino acid sequence derived therefrom, (a) of the natural HPV16-E7 protein. Sections a, b, c and d are given. These are separated from each other by arrows pointing downwards. The transitions a / b, b / c and c / d are also given. These are shown by arrows pointing upwards.
  • a DNA coding for the E7 protein (98 amino acids) of HPV 16 comprises the 297 base pairs indicated in FIG. 2 plus the stop codon TAA. This DNA was broken down into four parts (a-d): 1-30 (a), 31-120 (b), 121-210 (c) and 211-294 (d; without stop codon). In addition, the transitions a / b (10-60), b / c (100-144) and c / d (190-231; plus stop codon) were synthesized.
  • Fragments a and d were assembled by PCR; A HindIII cleavage site was inserted 5 'to a and an EcoRI cleavage site was inserted 3' to d (each with 6 bp spacer for better cleavage). In detail we proceeded as follows:
  • This fragment was isolated after gel electrophoresis and using the primer
  • Fragments c and b were assembled by PCR; An EcoRI cleavage site was used 5 'to c and a BamHI cleavage site (each with 6 bp spacer) was used 3' to b. In detail we proceeded as follows:
  • VII 5 '- (AGC AGT) Spacer (GGA TCC) BamHI A 120 CC ATC TAT TTC ATC CTC CTC CTC T 96 -3'
  • transitions a / b, b / c and c / d were assembled by PCR, 5 'of a / b using a BamHI cleavage site and 3' of c / d an Xbal cleavage site.
  • the procedure was as follows:
  • the fragments (VIII / IX) and X / Xl were linked using primers VIII and XI, so that the sequence 5'-spacer - BamHI - 7 -> 54/97 -> 144/187 -> 198-3 '( 117 bp) was created.
  • This fragment was linked together with the fragment (Xll / Xlll) using primers VIII and XIII, so that the sequence 5'-spacer - BamHI - 7 -> 54/97 -> 144/187 234 -> - Stop - Xbal - Spacer-3 '(171 bp) was created.
  • This sequence was cloned in the vector Bluescript after cleavage with BamHI and Xbal.
  • Example 2 Production and purification of a protein according to the invention
  • Example 1 The DNA obtained under 5 of Example 1 was inserted into the expression vector pQE-8 (Qiagen), which had been cleaved with HindIII and Xbal.
  • the expression plasmid pQE-8 / E7 was obtained.
  • pQE-8 / E7 was used to transform E.coli SG 13009 (see Gottesman, S. et al., J. Bacteriol. 148, (1981), 265-273).
  • the bacteria were cultivated in an LB medium with 100 ⁇ g / ml ampicillin and 25 ⁇ g / ml kanamycin and induced for 4 h with 60 ⁇ M isopropyl- ⁇ -D-thiogalactopyranoside (IPTG).
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • the bacteria were lysed by adding 6 M guanidine hydrochloride, and then chromatography (Ni-NTA resin) was carried out with the lysate in the presence of 8 M urea in accordance with the manufacturer's (Diagen) instructions for the chromatography material.
  • the bound fusion protein was eluted in a pH 3.5 buffer.
  • the fusion protein was subjected to an 18% SDS-polyacrylamide gel electrophoresis and stained with Coomassie blue (cf. Thomas, JO and Kornberg, RD, J. Mol. Biol. 149 (1975), 709-733) ). It was found that a (fusion) protein according to the invention can be produced in a highly pure form.
  • Example 3 Production and detection of an antibody according to the invention
  • a fusion protein according to the invention from Example 2 was subjected to 18% SDS polyacrylamide gel electrophoresis. After staining the gel with 4 M sodium acetate, an approximately 15 kD band was cut out of the gel and incubated in phosphate-buffered saline. Pieces of gel were sedimented before the protein concentration of the supernatant was determined by SDS-polyacrylamide gel electrophoresis, which was followed by a Coomassie blue staining. Animals were immunized with the gel-purified fusion protein as follows:
  • the rabbit's serum was tested in the immunoblot.
  • a fusion protein according to the invention from Example 1 was subjected to SDS-polyacrylamide gel electrophoresis and transferred to a nitrocellulose filter (cf. Khyse-Andersen, J., J. Bioche. Biophys. Meth. 10, (1984), 203-209).
  • Western blot analysis was performed as in Bock, C.-T. et al., Virus Genes 8, (1994), 215-229.
  • the nitrocellulose filter was incubated for one hour at 37 ° C. with a first antibody. This antibody was rabbit serum (1: 10,000 in PBS). After several washes with PBS, the nitrocellulose filter was incubated with a second antibody.
  • This antibody was an alkaline phosphorus phatase coupled goat monoclonal anti-rabbit IgG antibody (Dianova) (1: 5000) in PBS. After 30 minutes incubation at 37 ° C, several washing steps with PBS followed and then the alkaline phosphatase detection reaction with developer solution (36 ⁇ M 5 'bromo-4-chloro-3-indolylphosphate, 400 ⁇ M nitroblue tetrazolium, 100mM Tris-HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl 2 ) at room temperature until bands were visible.
  • developer solution 36 ⁇ M 5 'bromo-4-chloro-3-indolylphosphate, 400 ⁇ M nitroblue tetrazolium, 100mM Tris-HCl, pH 9.5, 100 mM NaCl, 5 mM MgCl 2
  • Antibodies were extracted from egg yolk and tested in a Western blot. Polyclonal antibodies according to the invention have been detected.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un polypeptide présentant des propriétés immunogènes et des fonctions biologiques modifiées d'une protéine. Ce polypeptide présente des segments de la protéine d'environ 10 à 40 acides aminés dans un ordre modifié par rapport à la protéine. L'invention concerne en outre un ADN codant un tel polypeptide et un procédé de production d'un tel polypeptide. L'invention concerne également l'utilisation de l'ADN et du polypeptide pour l'immunisation active, ainsi que des anticorps dirigés contre le polypeptide.
EP99932615A 1998-04-30 1999-04-30 Polypeptide presentant des proprietes immunogenes et des fonctions biologiques modifiees d'une proteine Withdrawn EP1073751A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19819476A DE19819476C1 (de) 1998-04-30 1998-04-30 Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
DE19819476 1998-04-30
PCT/DE1999/001331 WO1999055876A2 (fr) 1998-04-30 1999-04-30 Polypeptide presentant des proprietes immunogenes et des fonctions biologiques modifiees d'une proteine

Publications (1)

Publication Number Publication Date
EP1073751A2 true EP1073751A2 (fr) 2001-02-07

Family

ID=7866375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99932615A Withdrawn EP1073751A2 (fr) 1998-04-30 1999-04-30 Polypeptide presentant des proprietes immunogenes et des fonctions biologiques modifiees d'une proteine

Country Status (5)

Country Link
EP (1) EP1073751A2 (fr)
JP (1) JP2002512801A (fr)
AU (1) AU4895499A (fr)
DE (1) DE19819476C1 (fr)
WO (1) WO1999055876A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE354662T1 (de) 2001-03-23 2007-03-15 Deutsches Krebsforsch Modifizierte hpv e6- und e7-gene und -proteine als impfstoff
GB0120938D0 (en) * 2001-08-29 2001-10-17 Norchip As Detection of human papillomavirus E7 mRNA

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
DE3907721A1 (de) * 1989-03-10 1990-09-20 Behringwerke Ag Immunogene regionen auf dem e7-protein des humanen papillomvierus typ 16
WO1992010513A1 (fr) * 1990-12-12 1992-06-25 The University Of Queensland Vaccin a sous-unites contre le virus du papillome et peptides entrant dans sa composition
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9955876A3 *

Also Published As

Publication number Publication date
JP2002512801A (ja) 2002-05-08
AU4895499A (en) 1999-11-16
DE19819476C1 (de) 2000-01-05
WO1999055876A3 (fr) 2000-03-23
WO1999055876A2 (fr) 1999-11-04

Similar Documents

Publication Publication Date Title
DE19747418C1 (de) Inhibitor-Protein des wnt-Signalwegs
DE19717893A1 (de) Monofunktionelle Glycosyltransferasen
EP1141271B1 (fr) Selection d'anticorps monoclonaux
DE19850718C1 (de) Zellpermeabilität-vermittelndes Polypeptid
DE19819476C1 (de) Polypeptid mit immunogenen Eigenschaften und veränderten biologischen Funktionen eines Proteins
EP0842278B1 (fr) Proteine a activite de desoxyribonuclease
DE19611234C1 (de) Tyrosin-Phosphatase-verwandtes Protein
EP0848822A1 (fr) Procede pour deceler des anticorps specifiques diriges contre des proteines hpv
EP1015583B1 (fr) Proteine contenant un domaine srcr
EP1165797A2 (fr) Particules s'utilisant en therapie genique
DE19713434C1 (de) Protein zur Inhibierung von Apoptose
DE19650758C1 (de) PKD1-Fragmente mit Bindungsregionen für PKD1-spezifische Antikörper
DE19730997C1 (de) SRCR Domäne-enthaltendes Protein
EP0840789B1 (fr) Proteine apparentee a la transcetolase
DE19816186A1 (de) GDNF-kodierende DNA, Teile davon und GDNF-Varianten
DE19856882C1 (de) Spermatogenese-Protein
DE19534763C1 (de) FMR1-verwandtes Protein
EP1092769B1 (fr) Des "tags" polypeptidiques pour la détection et la purification de polypeptides
DE19835910C1 (de) Gen isoliert auf dem kurzen Arm des menschlichen Chromosoms 17
WO2000022117A1 (fr) Proteine tumorale
DE19644501A1 (de) GABA¶A¶-Rezeptoruntereinheit epsilon-verwandtes Protein

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001016

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LI NL SE

17Q First examination report despatched

Effective date: 20031222

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040504